Is CNTB or HIND more profitable?

Connect Biopharma has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Connect Biopharma's return on equity of -165.41% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -165.41% -121.58% Vyome -3,024.84% -197.33% -138.14%

Is IMA or HIND more profitable?

ImageneBio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. ImageneBio's return on equity of -38.99% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Vyome -3,024.84% -197.33% -138.14%

Do analysts recommend INMB or HIND?

Vyome has a consensus price target of $3.50, suggesting a potential upside of 77.66%. Given Vyome's higher possible upside, analysts clearly believe Vyome is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Vyome 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings & valuation, INMB or HIND?

Vyome has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 932.40 -$45.93M -$0.67 N/A Vyome $320K 43.22 -$10.26M -$3.37 N/A

Is INMB or HIND more profitable?

INmune Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. INmune Bio's return on equity of -82.87% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -82.87% -62.23% Vyome -3,024.84% -197.33% -138.14%

Do analysts prefer EXOZ or HIND?

Vyome has a consensus target price of $3.50, indicating a potential upside of 77.66%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Vyome 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is EXOZ or HIND more profitable?

eXoZymes has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Vyome's return on equity of -197.33% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Vyome -3,024.84% -197.33% -138.14%

Vyome (HIND) Competitors

$1.97 -0.04 (-1.99%)

Closing price 10/13/2026 03:59 PM Eastern

Extended Trading

$2.02 +0.05 (+2.34%)

As of 07:44 AM Eastern

Compare

HIND vs. CNTB, MREO, IMA, INMB, and EXOZ

Should you buy Vyome stock or one of its competitors? Vyome's main competitors and comparable companies include Connect Biopharma (CNTB), Mereo BioPharma Group (MREO), ImageneBio (IMA), INmune Bio (INMB), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vyome compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Connect Biopharma currently has a consensus price target of $5.88, suggesting a potential upside of 539.42%. Vyome has a consensus price target of $3.50, suggesting a potential upside of 77.66%. Given Connect Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Connect Biopharma is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Vyome	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Connect Biopharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market. Comparatively, Vyome has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Vyome has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	964.28	-$55.48M	-$1.19	N/A
Vyome	$320K	43.22	-$10.26M	-$3.37	N/A

Connect Biopharma has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Connect Biopharma's return on equity of -165.41% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Vyome	-3,024.84%	-197.33%	-138.14%

In the previous week, Connect Biopharma had 8 more articles in the media than Vyome. MarketBeat recorded 9 mentions for Connect Biopharma and 1 mentions for Vyome. Vyome's average media sentiment score of 1.82 beat Connect Biopharma's score of 0.17 indicating that Vyome is being referred to more favorably in the news media.

Company	Overall Sentiment
Connect Biopharma	Neutral
Vyome	Very Positive

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 33.0% of Vyome shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Connect Biopharma beats Vyome on 10 of the 15 factors compared between the two stocks.

How does Vyome compare to Mereo BioPharma Group?

Vyome (NASDAQ:HIND) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Vyome has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Vyome presently has a consensus target price of $3.50, indicating a potential upside of 77.66%. Mereo BioPharma Group has a consensus target price of $1.67, indicating a potential upside of 420.83%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Mereo BioPharma Group has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Mereo BioPharma Group's return on equity of -74.82% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Mereo BioPharma Group and 1 mentions for Vyome. Vyome's average media sentiment score of 1.82 beat Mereo BioPharma Group's score of 1.05 indicating that Vyome is being referred to more favorably in the media.

Company	Overall Sentiment
Vyome	Very Positive
Mereo BioPharma Group	Positive

22.1% of Vyome shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vyome has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	43.22	-$10.26M	-$3.37	N/A
Mereo BioPharma Group	$500K	102.20	-$41.88M	-$0.04	N/A

Summary

Mereo BioPharma Group beats Vyome on 10 of the 15 factors compared between the two stocks.

How does Vyome compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, ImageneBio had 1 more articles in the media than Vyome. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Vyome. Vyome's average media sentiment score of 1.82 beat ImageneBio's score of 1.38 indicating that Vyome is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
Vyome	Very Positive

ImageneBio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. ImageneBio's return on equity of -38.99% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Vyome	-3,024.84%	-197.33%	-138.14%

Vyome has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	60.16	-$45.35M	-$4.58	N/A
Vyome	$320K	43.22	-$10.26M	-$3.37	N/A

ImageneBio has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Vyome has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

ImageneBio presently has a consensus target price of $29.00, suggesting a potential upside of 583.96%. Vyome has a consensus target price of $3.50, suggesting a potential upside of 77.66%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Vyome	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 22.1% of Vyome shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 33.0% of Vyome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ImageneBio beats Vyome on 9 of the 15 factors compared between the two stocks.

How does Vyome compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

INmune Bio has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Vyome has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

Vyome has a consensus price target of $3.50, suggesting a potential upside of 77.66%. Given Vyome's higher possible upside, analysts clearly believe Vyome is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Vyome	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, INmune Bio and INmune Bio both had 1 articles in the media. Vyome's average media sentiment score of 1.82 beat INmune Bio's score of 0.91 indicating that Vyome is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Positive
Vyome	Very Positive

INmune Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. INmune Bio's return on equity of -82.87% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-82.87%	-62.23%
Vyome	-3,024.84%	-197.33%	-138.14%

Vyome has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	932.40	-$45.93M	-$0.67	N/A
Vyome	$320K	43.22	-$10.26M	-$3.37	N/A

Summary

Vyome beats INmune Bio on 8 of the 15 factors compared between the two stocks.

How does Vyome compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

22.1% of Vyome shares are held by institutional investors. 58.0% of eXoZymes shares are held by company insiders. Comparatively, 33.0% of Vyome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, eXoZymes had 1 more articles in the media than Vyome. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Vyome. Vyome's average media sentiment score of 1.82 beat eXoZymes' score of 1.18 indicating that Vyome is being referred to more favorably in the news media.

Company	Overall Sentiment
eXoZymes	Positive
Vyome	Very Positive

eXoZymes has a beta of 3.19, indicating that its stock price is 219% more volatile than the broader market. Comparatively, Vyome has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Vyome has a consensus target price of $3.50, indicating a potential upside of 77.66%. Given Vyome's stronger consensus rating and higher probable upside, analysts plainly believe Vyome is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Vyome	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

eXoZymes has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Vyome's return on equity of -197.33% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Vyome	-3,024.84%	-197.33%	-138.14%

eXoZymes has higher earnings, but lower revenue than Vyome. eXoZymes is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	609.81	-$9.16M	-$1.19	N/A
Vyome	$320K	43.22	-$10.26M	-$3.37	N/A

Summary

Vyome beats eXoZymes on 8 of the 15 factors compared between the two stocks.

Get Vyome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIND vs. The Competition

Export

Metric	Vyome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.11M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.78	202.90	19.69
Price / Sales	43.22	1,146.43	561.48	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	2.94	16.70	10.61	6.03
Net Income	-$10.26M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-3.43%	-4.43%	-2.89%	-2.34%
1 Month Performance	-4.37%	-12.49%	-7.37%	-5.31%
1 Year Performance	-62.83%	7.63%	3.00%	-2.94%

Vyome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIND Vyome	2.497 of 5 stars	$1.97 -2.0%	$3.50 +77.7%	-60.7%	$14.11M	$320K	N/A	18	Gap Up
CNTB Connect Biopharma	3.0127 of 5 stars	$0.94 +4.3%	$6.14 +550.2%	-49.5%	$57.02M	$60K	N/A	64	Analyst Forecast
MREO Mereo BioPharma Group	3.6513 of 5 stars	$0.35 +0.8%	$1.67 +372.4%	-84.0%	$55.91M	$500K	N/A	39	Positive News
IMA ImageneBio	3.392 of 5 stars	$4.61 +0.2%	$29.00 +529.1%	-44.9%	$52.22M	$800K	N/A	18	Positive News Gap Down
INMB INmune Bio	0.4983 of 5 stars	$1.86 -0.5%	N/A	-8.2%	$51.90M	$50K	N/A	21	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIND) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vyome (HIND) Competitors

HIND vs. CNTB, MREO, IMA, INMB, and EXOZ

How does Vyome compare to Connect Biopharma?

Summary

How does Vyome compare to Mereo BioPharma Group?

Summary

How does Vyome compare to ImageneBio?

Summary

How does Vyome compare to INmune Bio?

Summary

How does Vyome compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIND vs. The Competition

Vyome Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vyome (HIND) Competitors

HIND vs. CNTB, MREO, IMA, INMB, and EXOZ

How does Vyome compare to Connect Biopharma?

Do analysts recommend CNTB or HIND?

Which has more volatility & risk, CNTB or HIND?

Which has preferable earnings and valuation, CNTB or HIND?

Is CNTB or HIND more profitable?

Does the media favor CNTB or HIND?

Do institutionals & insiders have more ownership in CNTB or HIND?

Summary

How does Vyome compare to Mereo BioPharma Group?

Which has more volatility and risk, HIND or MREO?

Do analysts recommend HIND or MREO?

Is HIND or MREO more profitable?

Does the media refer more to HIND or MREO?

Do insiders and institutionals believe in HIND or MREO?

Which has better earnings and valuation, HIND or MREO?

Summary

How does Vyome compare to ImageneBio?

Does the media favor IMA or HIND?

Is IMA or HIND more profitable?

Which has better valuation & earnings, IMA or HIND?

Which has more volatility and risk, IMA or HIND?

Do analysts rate IMA or HIND?

Do institutionals & insiders believe in IMA or HIND?

Summary

How does Vyome compare to INmune Bio?

Do institutionals and insiders hold more shares of INMB or HIND?

Which has more risk and volatility, INMB or HIND?

Do analysts recommend INMB or HIND?

Does the media favor INMB or HIND?

Is INMB or HIND more profitable?

Which has higher earnings & valuation, INMB or HIND?

Summary

How does Vyome compare to eXoZymes?

Do insiders & institutionals believe in EXOZ or HIND?

Does the media favor EXOZ or HIND?

Which has more risk & volatility, EXOZ or HIND?

Do analysts prefer EXOZ or HIND?

Is EXOZ or HIND more profitable?

Which has preferable earnings & valuation, EXOZ or HIND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIND vs. The Competition

Vyome Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools